Teleflex Inc (TFX) Stock Price & Analysis
Teleflex Inc (TFX) rose 3.04% to USD 135.75 as of June 9, 2026 at 23:45 UTC, according to Nexqual real-time market data.
TFX last closed at USD 131.74; the session ranged USD 132.63–136.15 on volume of 473,363 shares. Market capitalization is $6.01B, with a 52-week range of USD 100.18–139.67 (NYQ). Source: Nexqual, June 9, 2026 at 23:45 UTC.
Key Statistics (as of June 9, 2026 at 23:45 UTC)
| Price | USD 135.75 |
|---|---|
| Change | ▲ 3.04% (up) |
| Previous Close | USD 131.74 |
| Open | USD 132.35 |
| Day Range | USD 132.63 – 136.15 |
| 52-Week Range | USD 100.18 – 139.67 |
| Volume | 473,363 shares |
| Market Cap | $6.01B |
| Exchange | NYQ |
Technical Analysis (TFX)
Nexqual's technical model rates TFX "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:45 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.58 (neutral) |
| vs SMA50 | Above (USD 127.7) |
| MACD | 1.17 (positive) |
Analyst Ratings (TFX)
Wall Street analysts rate TFX "None" based on 9 analysts, with a mean price target of USD 143.67 (range USD 135–155), per Nexqual as of June 9, 2026 at 23:45 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 9 |
| Mean Target | USD 143.67 |
| High Target | USD 155 |
| Low Target | USD 135 |
| Buy / Hold / Sell | 3 / 8 / 0 |
Earnings (TFX)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD 1.27 |
| Revenue Estimate | $559.02M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.39 vs est 1.21 ▲ beat |
| 2025-12-31 | USD 1.93 vs est 3.75 ▼ miss |
| 2025-09-30 | USD 3.67 vs est 3.38 ▲ beat |
| 2025-06-30 | USD 3.73 vs est 3.37 ▲ beat |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Financials & Fundamentals (TFX)
| Total Revenue | $2.13B |
|---|---|
| Revenue Growth (YoY) | +32.30% |
| Gross Margin | +55.33% |
| Operating Margin | +8.36% |
| Profit Margin | -47.43% |
| ROE | +0.04% |
| Debt / Equity | 88.79 |
| Current Ratio | 2.55 |
| Total Cash | $333.06M |
| Total Debt | $2.74B |
| Free Cash Flow | $-3.68M |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Financial Health Score (TFX)
Nexqual rates Teleflex Inc's overall financial health "Weak" across five dimensions, as of June 9, 2026 at 23:45 UTC.
| Growth | Critical — Revenue -35% YoY (annual), sharp decline |
|---|---|
| Profitability | Strong — Gross margin 55%, operating 8% |
| Balance Sheet | Mixed — $333M cash vs $2.74B debt |
| Cash Flow | Weak — FCF negative: -$4M, burning cash |
| Efficiency | Weak — ROE 0%, ROA 2.3% |
Ownership (TFX)
| Insider Ownership | +0.47% |
|---|---|
| Institutional Ownership | +110.92% |
| Shares Outstanding | 44.27M |
| Float | 44.10M |
| Short % of Float | +8.23% |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
Leadership (TFX)
Teleflex Inc is led by Lawrence Soren Keusch, Vice President of Investor Relations & Strategy Development, per Nexqual as of June 9, 2026 at 23:45 UTC.
| Vice President of Investor Relations & Strategy Development | Lawrence Soren Keusch |
|---|---|
| Vice President of Corporate Development | Matt Tomkin |
| President & GM of Surgical | James Ferguson |
| President & GM of Interventional | Matthew James |
Major Backers & Investors (TFX)
Notable institutional backers of Teleflex Inc include T. Rowe Price, Janus Henderson Group PLC, JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund, according to Nexqual as of June 9, 2026 at 23:45 UTC.
Active Investors
| Investor | Stake |
|---|---|
| T. Rowe Price | 12.78% |
| Janus Henderson Group PLC | 9.69% |
| JANUS INVESTMENT FUND-Janus Henderson Enterprise Fund | 6.52% |
| BAUPOST GROUP LLC/MA | 3.6% |
| Sessa Capital IM, L.P. | 3.45% |
| Fuller & Thaler Asset Management Inc. | 3.08% |
| Citadel | 2.65% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 18.26% |
| Vanguard Group | 18.05% |
| State Street | 3.39% |
Source: Nexqual, June 9, 2026 at 23:45 UTC.
From Teleflex Inc's Latest SEC 10-K Filing (filed 2026-02-27)
Key Strengths & Strategy (as disclosed to the SEC)
- Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
- It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters.
- In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands.
- It serves hospitals, healthcare providers, and medical device manufacturers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| STE | STERIS plc (Ireland) | USD 212.88 | ▲ 0.25% |
| COO | The Cooper Companies, Inc. | USD 68.62 | ▲ 1.9% |
| MTD | Mettler-Toledo International, I | USD 1,162.79 | ▲ 0.73% |
| IEX | IDEX Corporation | USD 222.14 | ▲ 3.15% |
| WST | West Pharmaceutical Services, I | USD 334.66 | ▲ 6.41% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:45 UTC. This page is informational and not investment advice.